ReviewEJHaem2025
Direct Oral Anticoagulants Compared to Warfarin in Patients with Intermediate- to High-Risk Pulmonary Embolism: A Systematic Review and Meta-Analysis.
Review in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite recent advances in clinical therapeutics in patients with venous thromboembolism, uncertainty remains regarding the optimal anticoagulation strategy in patients with intermediate- to high-risk pulmonary embolism. We aimed to evaluate the direct oral anticoagulants' effectiveness and safety compared to warfarin in patients with intermediate- and high-risk pulmonary embolism. Methods: In this meta-analysis, we systematically searched databases PubMed, EMBASE, Web of Science, and the Cochrane Library from their inception to April 30, 2024, for eligible studies that satisfy inclusion criteria. We included both randomized clinical trials and observational studies reporting on patients diagnosed with intermediate-risk or high-risk pulmonary embolism who were prescribed warfarin or direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban). Two independent reviewers extracted relevant data from included studies based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Pooled odds ratios were derived from the included studies using the random-effects model. The primary outcomes were the rate of venous thromboembolism recurrence and all-cause mortality. Secondary outcomes were major and minor bleeding. Results: Six studies, five observational and one randomized ( Conclusion: In patients with intermediate- to high-risk pulmonary embolism, with or without advanced therapy use, stabilized on direct oral anticoagulants, efficacy and safety outcomes were comparable to those on warfarin, with a trend towards less risk of major and minor bleeding events. Trial registration: International PROSPERO database number: CRD42024499532.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.